Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gynostemma + prednisone
- Development stage
- Phase 2
- Lead developer
- Shaanxi Ankang Medicinal Plant Development Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gynostemma + prednisone is a combination pharmaceutical product consisting of gypenosides (saponins extracted from the traditional Chinese medicinal herb *Gynostemma pentaphyllum*) and the synthetic corticosteroid prednisone. Developed by the Shaanxi Ankang Medicinal Plant Development Research Institute, this combination is primarily being investigated for the treatment of systemic lupus erythematosus (SLE). The gypenoside component is believed to exert anti-inflammatory and immunomodulatory effects, potentially through the regulation of autophagy via the Sirt1/AMPK/mTOR signaling pathway. Prednisone serves as a potent glucocorticoid receptor agonist, suppressing the overactive immune response characteristic of SLE. The drug is currently in Phase II clinical development in China, where it is being evaluated for its ability to reduce disease activity as measured by the SLEDAI score compared to prednisone monotherapy.
- Other names
- gynostemma-prednisone tabletsgypenosides + prednisone
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)GR (Glucocorticoid receptor)mTOR (Mammalian target of rapamycin kinase)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on gynostemma + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gynostemma + prednisone.